Raggi, PaoloBellasi, AntonioSinha, SmeetaBover, JordiRodriguez, MarianoKetteler, MarkusBushinsky, David A.Garg, RekhaPerelló, JoanGold, AlexChertow, Glenn M.2022-04-202022-04-202020-11-04Raggi P, Bellasi A, Sinha S, Bover J, Rodriguez M, Ketteler M, et al. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. Kidney Int Rep. 2020 Nov 4;5(12):2178-2182http://hdl.handle.net/10668/3550Introduction Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving maintenance hemodialysis. In this analysis, we assessed the efficacy of SNF472 in prespecified patient subgroups. Methods In a randomized clinical trial SNF472 300 mg, SNF472 600 mg, or placebo were infused thrice weekly in 91, 92, and 91 patients receiving maintenance hemodialysis and with CAC at baseline, respectively. In prespecified subanalyses, the percent change in CAC volume score (CACvs) from baseline to week 52 in modified intention-to-treat (mITT) and per-protocol (PP) populations was calculated in the following subgroups: age, sex, diabetes mellitus, dialysis vintage, prior atherosclerotic cardiovascular disease, baseline use of non-calcium and calcium-based phosphate binders, calcimimetics, activated vitamin D, warfarin, and statins. Results In the main trial, SNF472 significantly reduced CACvs progression compared with placebo (11% versus 20% mITT analyses; P = 0.016; 8% vs. 24% PP analyses; P < 0.001). Treatment differences for CACvs progression were similar across all subgroups, and all interaction P values were non-significant in mITT and PP analyses. Conclusions SNF472 treatment for 52 weeks reduced CACvs progression compared with placebo in a broad range of patients receiving maintenance hemodialysis. Future studies will determine the impact of SNF472 on cardiovascular events in this population.enAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Coronary calcificationVascular calcificationHemodialysisCalcificación vascularDiálisis renalEnfermedades RenalesSNF472Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Biological Factors::Blood Coagulation Factors::CalciumMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Lipid Regulating Agents::Hypolipidemic Agents::Anticholesteremic Agents::Hydroxymethylglutaryl-CoA Reductase InhibitorsMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Pyrans::Benzopyrans::Coumarins::4-Hydroxycoumarins::WarfarinMedical Subject Headings::Anatomy::Cardiovascular System::Blood Vessels::Arteries::Coronary VesselsMedical Subject Headings::Diseases::Cardiovascular DiseasesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::CrystallizationMedical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic::Intention to Treat AnalysisMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Renal Replacement Therapy::Renal DialysisMedical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Phosphorus Compounds::Phosphorus Acids::Phosphoric Acids::PhosphatesMedical Subject Headings::Diseases::Endocrine System Diseases::Diabetes MellitusMedical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Calcium Compounds::Calcium Phosphates::Apatites::HydroxyapatitesMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Secosteroids::Vitamin Dresearch article33305110open access10.1016/j.ekir.2020.09.0322468-0249PMC7710828